Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

EST Psyence Biomedical (PBM) files to sell 3.075M common shares for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

These companies are considered the “Big 3” in the PBM industry, controlling roughly 60 percent of the market. “The FTC staff’s second interim report finds that the three major pharmacy ...